Congjing CJ1004 series portable ultrashort wave therapy instrument obtained class II certificate of medical equipment

At present, pain has become an important challenge in the field of health in China, ranking third after cardiovascular and cerebrovascular diseases and tumors. Statistics show that the number of chronic pain patients in China has exceeded 300 million, and it continues to grow at a rate of about 10 to 20 million people every year. However, for a long time, most patients lack a correct understanding of pain, often think that pain is not a disease, and hold the concept of "medicine is three poisons", and would rather endure pain than accept treatment; The situation of pain prevention and treatment is not optimistic.

Conjing Group focuses on RF moxibustion therapy research and has brought CJ1004 portable ultra-short wave therapy instrument series of innovative products. The advent of this device has not only been recognized by the State Food and Drug Administration and obtained the registration certificate of Class II medical devices, but also brought the Gospel to the majority of pain patients. As the "World Analgesia Day" approaches, we have reason to believe that the portable ultra-short wave therapy device will become a major breakthrough in the field of pain management, bringing more health and hope to pain patients.

In recent years, with the development of medical technology, the application range of rehabilitation treatment is more and more wide, ultrashort wave has the characteristics of simple operation and non-invasive, and has obtained better clinical results in orthopedics, pain and other diseases. Rf moxibustion therapy is a cross-fusion and innovative technology in the field of medical treatment and health. Through traditional Chinese medicine and physical therapy, it improves blood circulation, strengthens tissue nutrition, enhances immunity and phagocytic cell number, and promotes the dissipation and absorption of edema and inflammatory infiltration, which is widely trusted by medical staff and patients.
Liu Simin, teacher of Acupuncture and moxibustion Department of Hubei Hospital of Traditional Chinese Medicine, published "Clinical Observation of Thunder fire moxibustion combined with ultra-short wave Treatment of wind-cold-dampness arthritis Knee Osteoarthritis" in the National Science and Technology support Plan project and the fund project of Hubei Provincial Health Department. From October 2018 to October 2019, 65 patients with wind-cold-dampness arthritis of knee osteoarthritis treated in Hubei Hospital of Traditional Chinese Medicine were selected as the study subjects and given ultrashort wave treatment; The results showed that after treatment, the swelling degree of the knee joint was significantly reduced, and the symptoms of movement limitation, joint cold pain, joint stiffness, cold pain in the back and back were significantly improved.
According to Prescient & Strategic Intelligence research, the global chronic pain treatment market will generate $80.767 billion in revenue in 2020 and is expected to reach $162.175 billion by 2030. The Compound Annual Growth Rate (CAGR) is 7.2%, of which the Chinese market is expected to contribute the highest growth rate. China Pain Medicine Report 2020 shows that there are more than 300 million chronic pain patients in China, with an annual increase of 10-20 million, and nearly 40% of patients spend between 1000-5000 yuan on pain treatment within 6 months. Assuming that the treatment rate of chronic pain is 30%, the per capita annual treatment cost is 1,000 yuan. It is estimated that the market size of China's chronic pain treatment is about 90 billion yuan.

Musculoskeletal pain (CMP) is the most common chronic pain and will account for the largest share of the chronic pain treatment market in 2020. From the demand side, the penetration rate of musculoskeletal pain patients in China is high and the trend is younger, the population covers a wide range and the demand is large. According to the survey of Zhongkang Consumer Research Center, the penetration rate of musculoskeletal joint pain patients in China will exceed 40% in 2022. The incidence rate increases with age, the penetration rate of people over 56 years old exceeds 60%, while affected by improper exercise or bad living habits, the penetration rate of young adults under 35 years old is as high as 42.4%.

Benefiting from the clinical advantages of Jingshi moxibustion series products and broad market prospects, while the company's marketing efforts to increase the scale effect, since the listing of rapid growth in sales, user feedback evaluation is quite high, it is expected that the future CONGJING Group will occupy a dominant position in the field of ultra-short wave.